Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Sarcoma 1

Conditions

Glioblastoma 6Central Nervous System Neoplasms 5Gliosarcoma 4Brain Neoplasms 4Glioma 3Astrocytoma 3Sarcoma 1Rectal Neoplasms 1Oligodendroglioma 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Melanoma 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Temozolomide 69Bevacizumab 40Radiotherapy 22Magnetic Resonance Spectroscopy 20Irinotecan 17Specimen Handling 10Carboplatin 10Carmustine 9X-Rays 7Radiation 7olaparib 6Surgical Procedures, Operative 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6Nivolumab 6Everolimus 6Cyclophosphamide 6Biopsy 6trametinib 5Thalidomide 5Cisplatin 5pembrolizumab 4palbociclib 4fluorodopa F 18 4erdafitinib 4dabrafenib 4Lomustine 4Etoposide 4Drug Therapy 4Doxorubicin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Glioma × O(6)-benzylguanine × Clear all
NCT00005081 2014-08-21

Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma

Duke University

Phase 2 Completed
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00613093 2014-07-09

Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma

Duke University

Phase 2 Completed
67 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Central Nervous System Neoplasms

NCT00389090 2012-02-09

A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma

Keryx / AOI Pharmaceuticals, Inc.

Phase 2 Terminated
32 enrolled
CNS

Astrocytoma, Glioma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡